$1.38
-0.02 (-1.43%)
Open$1.39
Previous Close$1.40
Day High$1.39
Day Low$1.34
52W High$6.19
52W Low$1.05
Volume—
Avg Volume226.7K
Market Cap2.41M
P/E Ratio—
EPS$-2.51
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,435.5% upside
Current
$1.38
$1.38
Target
$21.19
$21.19
$14.35
$21.19 avg
$22.63
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 842.6K | 775.9K | 707.6K |
| Net Income | 53.5K | 41.0K | 38.8K |
| Profit Margin | 6.3% | 5.3% | 5.5% |
| EBITDA | 84.6K | 70.9K | 63.0K |
| Free Cash Flow | 39.3K | 30.9K | 34.5K |
| Rev Growth | +2.0% | +16.5% | +21.7% |
| Debt/Equity | 0.16 | 0.21 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |